First Manhattan’s iBio IBIO Stock Holding History

First Manhattan’s Portfolio IBIO Stock Details IBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-42	Closed	-$22K	–	1613
2021 Q3	$22K	Hold	42	–	–	﹤0.01%	1149
2021 Q2	$31K	Hold	42	–	–	﹤0.01%	1080
2021 Q1	$32K	Buy	+42	New	+$36.6K	﹤0.01%	1052

Other funds holding IBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

First Manhattan's IBIO Position: Q4 2021 in Review

First Manhattan sold out of iBio (IBIO) in Q4 2021, closing a stake of 42 shares — an estimated $22K sold.

First Manhattan first reported a position in IBIO in Q1 2021 and held it in 3 quarters. The position peaked at $32K in Q1 2021. 77 funds tracked by Wall St. Rank hold IBIO as of Q4 2021.

First Manhattan reported no remaining iBio position as of Q4 2021 after selling out during the quarter.
First Manhattan sold 42 iBio shares in Q4 2021, an estimated $22K.
First Manhattan first reported a position in iBio in Q1 2021 and held it in 3 quarters.
First Manhattan's iBio position peaked at $32K in Q1 2021.
77 funds tracked by Wall St. Rank held iBio as of Q4 2021.

Based on First Manhattan's 13F filing for Q4 2021, filed 14 Feb 2022.